Close

Roth Affirms Applied Genetic Tech (AGTC) at 'Neutral' Amid CNGA3 IND Filing; Application Expands Present Pipeline

October 20, 2016 8:20 AM EDT Send to a Friend
Roth Capital affirms Applied Genetic Technologies Corporation (Nasdaq: AGTC) at Neutral with a price target of $12 after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login